AI assistant
Evotec SE — Regulatory Filings 2015
Jan 19, 2015
151_rns_2015-01-19_abc9b603-5036-481a-99ab-a4ce9fc00d69.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 19 January 2015 07:30
Evotec and C4XD enter collaboration to identify pre-clinical development candidates for stress-related addictive disorder programme
DGAP-News: Evotec AG / Key word(s): Miscellaneous
2015-01-19 / 07:30
* Collaboration leverages the breadth & experience of Evotec's drug
discovery infrastructure across chemistry & biology
* Efforts will combine the use of C4XD's proprietary NMR technology to
conformational ligand design with Evotec's state-of-the-art biology &
computational and medicinal chemistry capabilities
Hamburg, Germany - 19 January 2015: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced a research collaboration
with C4X Discovery Holdings plc ("C4XD") to optimise Orexin-1 selective
inhibitors discovered through C4XD's unique NMR technology. Evotec will
apply its drug discovery platform with C4XD to further develop several
series of Orexin-1 selective inhibitors.
Activation of the orexin-1 receptor in the brain is associated with
stress-related addictive disorders (e.g. for alcohol, nicotine, cocaine and
opiates), while the activation of the orexin-2 receptor is associated with
biorhythms and wakefulness. Identification and development of selective
compounds that inhibit the orexin-1 pathway thus should provide treatments
for addiction avoiding the sedative effects associated with inhibition of
orexin-2.
"We are delighted to work with C4XD on this strategic collaboration. C4XD
has an exciting technology that can really revolutionise how rational drug
design is conducted, particularly on targets like Orexin where the
conformation of drug-like ligands is particular important to on-target
potency. With Evotec's complementary expertise in computational chemistry,
medicinal chemistry and pharmacology we look forward to help drive C4XD's
objective to develop compounds to treat addictive disorders", said Dr Mario
Polywka, Chief Operating Officer of Evotec.
"Through this collaboration with Evotec, we expect our novel biological
discoveries and medical insights will be effectively and efficiently
progressed into a state-of-the-art drug discovery and development
programme. The collaboration is already demonstrating the benefit of an
alliance in accelerating drug discovery projects", said Piers Morgan, CEO
of C4XD.
No financial details were disclosed.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners including
Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing
development partnerships and product candidates both in clinical and
pre-clinical development. These include partnerships with Boehringer
Ingelheim and MedImmune in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT C4X DISCOVERY HOLDINGS PLC
C4XD is a Manchester-based company focused on optimising drug discovery and
design. It was founded in 2008 as a spin-out from the University of
Manchester. The company uses its NMR-based technology to solve the dynamic
3D structures of a broad range of biomolecules, including peptides,
cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology
shows what shapes active molecules prefer to adopt, it provides
high-quality templates for drug discovery and design, and valuable
information for drug candidate optimisation. In addition, the data is
generated faster and more reliably than standard techniques such as X-ray
co-crystallography or molecular modelling. C4XD is using its technology in
collaboration with the pharmaceutical industry and to build its own
proprietary pipeline of high-value therapeutic candidates.
www.c4xdiscovery.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
2015-01-19 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
314271 2015-01-19